First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery

• Published in: PloS one Vol. 12; no. 11; p. e0188899
• Main Authors: Pfeiffer, Norbert, Voykov, Bogomil, Renieri, Giulia, Bell, Katharina, Richter, Paul, Weigel, Melanie, Thieme, Hagen, Wilhelm, Barbara, Lorenz, Katrin, Feindor, Martin, Wosikowski, Katja, Janicot, Michel, Päckert, Daniela, Römmich, Regina, Mala, Carola, Fettes, Petra, Leo, Eugen
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 30.11.2017; Public Library of Science (PLoS)
• Subjects: Biology and Life Sciences; Care and treatment; Control; Dosage and administration; Genetic aspects; Intraocular pressure; Intravenous injections; Medicine and Health Sciences; Oligonucleotides; Open-angle glaucoma; Safety and security measures; Social Sciences; Trabeculectomy; Transforming growth factors

To evaluate the safety and tolerability of intravitreal ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in patients with primary open angle glaucoma (POAG) undergoing trabeculectomy (TE; glaucoma filtration surgery). In this prospective phase...